Response to: Correspondence on "Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation" by Braaten et al.
Response to: Correspondence on "Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation" by Braaten et al.
复制标题
回应：Braaten 等人关于“免疫检查点抑制剂诱导的炎症性关节炎在免疫治疗停止后持续存在”的通讯。
DOI：
10.1136/annrheumdis-2019-216892
复制
发表时间：
2022
影响因子：
27.4
通讯作者：
Shah,AmiA
中科院分区：
文献类型：
--
作者：
Cappelli,LauraC;Bingham,CliftonO;Braaten,Tawnie;Shah,AmiA
我们有兴趣阅读Ceccarelli等人关于他们在Sapienza大学使用免疫检查点抑制剂（ICI）诱导的炎症性关节炎（IA）的经验的信。1他们的研究结果支持ICI诱导的IA是一种具有不同结局的异质性疾病。队列研究的差异也可能使我们深入了解ICI诱导IA持续存在的风险因素。作者指出了两组之间的一个主要差异，即ICI治疗的类型。事实上，在我们的队列中，抗细胞毒性T淋巴细胞相关蛋白4（CTLA-4）/抗程序性细胞死亡蛋白-1（PD-1）联合治疗是持续性IA的独立风险因素，2他们的研究仅包括接受抗PD-1药物治疗的患者。还有其他几个相关的差异。首先，与我们的研究相比，患者在诊断IA和开始使用皮质类固醇之前使用ICI的持续时间较短。在我们的队列中，ICI治疗的持续时间也是IA持续性的独立风险因素。2第二，研究中的所有患者都经过了IA评估，这可能导致早期诊断和潜在的轻度疾病。没有具体报告疾病活动性，但IA的发生率（9.7%）高于任何先前发表的研究，表明包括轻度疾病。[1]显然，需要多中心的国际努力来评估ICI诱导的IA的纵向结果。
We were interested to read the letter by Ceccarelli et al regarding their experience with Immune checkpoint inhibitor (ICI)-induced inflammatory arthritis (IA) at Sapienza University. 1 Their findings support that ICI-induced IA is a heterogeneous disease with differing outcomes. The differences in the cohorts studied may also give us insight into the risk factors for persistence in ICI-induced IA. The authors point out one main difference between the cohorts, type of ICI therapy. Indeed, combination anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)/anti-programmed cell death protein-1 (PD-1) therapy was an independent risk factor for persistent IA in our cohort, 2 and their study included only patients on anti-PD-1 agents. There are several other relevant differences. First, the patients had a shorter duration of ICI use before IA was diagnosed and corticosteroids were started as compared with our study. Duration of ICI therapy was also an independent risk factor for IA persistence in our cohort. 2 Second, all patients in the study were evaluated deliberately for IA which likely led to earlier diagnosis and potentially milder disease. Disease activity is not specifically reported, but the higher incidence of IA (9.7%) than in any previously published studies suggests that milder disease was included. 1 The need for multicentre, international efforts to characterise longitudinal outcomes for ICI-induced IA is apparent.